FDA Approves First DNA Medicine, VOCERYQ, to Reduce Surgeries in Adults with RRP
INOVIO’s VOCERYQ receives FDA accelerated approval as the first DNA medicine in the US, reducing surgery frequency in adults with recurrent respiratory papillomatosis.
INOVIO’s VOCERYQ receives FDA accelerated approval as the first DNA medicine in the US, reducing surgery frequency in adults with recurrent respiratory papillomatosis.
B. Riley rates Precigen Buy on Papzimeos, the first FDA-approved adult RRP therapy, plus Q2 profit and management’s year-end cash break-even goal.